BTK x EGFR T790M

To evaluate the efficacy, safety, pharmacokinetic characteristics, the relationship between exposure level and efficacy and safety, blood-brain barrier penetration rate, PK characteristics in cerebrospinal fluid, and the relationship between receptor occupancy and efficacy of crinetinib in the treatment of subjects with relapsed/refractory B-cell lymphoma.

Primary objective: To evaluate the safety and efficacy of crinetinib capsules in patients with advanced non-small cell lung cancer (NSCLC) with brain metastases or progression of brain metastases after treatment with EGFR inhibitors. Secondary objective: To evaluate the blood-brain barrier (BBB) penetration rate and PK characteristics of crinetinib in cerebrospinal fluid (CSF) in patients with advanced NSCLC with brain metastases or progression of brain metastases after treatment with EGFR inhibitors. To assess the relationship between the exposure level of crinetinib and its efficacy and safety.

To evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor efficacy of single and subsequent multiple oral administration of criptinib capsules in patients with advanced non-small cell lung cancer with EGFR gene T790M mutation, and to provide a basis for the design of subsequent clinical trials.